CN1259948A - 6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物 - Google Patents
6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物 Download PDFInfo
- Publication number
- CN1259948A CN1259948A CN98806072A CN98806072A CN1259948A CN 1259948 A CN1259948 A CN 1259948A CN 98806072 A CN98806072 A CN 98806072A CN 98806072 A CN98806072 A CN 98806072A CN 1259948 A CN1259948 A CN 1259948A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- amino
- methyl
- pyrimidine
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine compounds Chemical class 0.000 title claims description 837
- 150000001875 compounds Chemical class 0.000 claims abstract description 154
- 125000003118 aryl group Chemical group 0.000 claims abstract description 92
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 75
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 72
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 42
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 206010040047 Sepsis Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 9
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 9
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 206010015037 epilepsy Diseases 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 87
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 41
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 40
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 claims description 33
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 32
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 claims description 25
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 24
- 125000000304 alkynyl group Chemical group 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 16
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 15
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 15
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 12
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims description 12
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002585 base Substances 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 150000004820 halides Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 11
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 11
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 9
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 9
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical group COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 9
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 9
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 8
- JSJORBSFQSEADC-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(5-nitrothiophen-2-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C([N+]([O-])=O)S1 JSJORBSFQSEADC-UHFFFAOYSA-N 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims description 7
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims description 6
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 6
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 6
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims description 6
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- AYEKAYFYECOMKD-UHFFFAOYSA-N 6-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=CC(Br)=C1 AYEKAYFYECOMKD-UHFFFAOYSA-N 0.000 claims description 5
- SESABXYEJPEPAF-UHFFFAOYSA-N 6-(3-chlorophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=CC(Cl)=C1 SESABXYEJPEPAF-UHFFFAOYSA-N 0.000 claims description 5
- GZAXXRAUDHWADA-UHFFFAOYSA-N 6-(3-fluoro-4-methylphenyl)-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=C(F)C(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 GZAXXRAUDHWADA-UHFFFAOYSA-N 0.000 claims description 5
- SKGNDELMCGFBNW-UHFFFAOYSA-N 6-(4-chlorophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(Cl)C=C1 SKGNDELMCGFBNW-UHFFFAOYSA-N 0.000 claims description 5
- DVLBGTRBWWVIHA-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(4-phenylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(C=2C=CC=CC=2)C=C1 DVLBGTRBWWVIHA-UHFFFAOYSA-N 0.000 claims description 5
- LWJJWCUIWNFIMD-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(4-pyrimidin-5-ylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(C=2C=NC=NC=2)C=C1 LWJJWCUIWNFIMD-UHFFFAOYSA-N 0.000 claims description 5
- FMCJKBDHGIEHMU-UHFFFAOYSA-N 6-(4-methylphenyl)-7-[4-(2-pyridin-2-ylethenyl)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C(C=C1)=CC=C1C=CC1=CC=CC=N1 FMCJKBDHGIEHMU-UHFFFAOYSA-N 0.000 claims description 5
- VBQQIWVCTLIEBG-UHFFFAOYSA-N 6-(4-methylphenyl)-7-[4-(trifluoromethoxy)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(OC(F)(F)F)C=C1 VBQQIWVCTLIEBG-UHFFFAOYSA-N 0.000 claims description 5
- XGOQVLJOQCXJBJ-UHFFFAOYSA-N 6-(cyclohexylmethyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1CC1CCCCC1 XGOQVLJOQCXJBJ-UHFFFAOYSA-N 0.000 claims description 5
- UIERGJMSJNOJMO-UHFFFAOYSA-N 6-[(3-bromophenyl)methyl]-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C=1C=CC(Br)=CC=1CC=1C=C2C(N)=NC=NC2=NC=1C1=CC=CS1 UIERGJMSJNOJMO-UHFFFAOYSA-N 0.000 claims description 5
- YVUNAEMEQFGBJH-UHFFFAOYSA-N 6-[(3-fluorophenyl)methyl]-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C=1C=CC(F)=CC=1CC=1C=C2C(N)=NC=NC2=NC=1C1=CC=CS1 YVUNAEMEQFGBJH-UHFFFAOYSA-N 0.000 claims description 5
- ZNRYWQJEDZQRGQ-UHFFFAOYSA-N 6-[(4-bromophenyl)methyl]-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C=1C=C(Br)C=CC=1CC=1C=C2C(N)=NC=NC2=NC=1C1=CC=CS1 ZNRYWQJEDZQRGQ-UHFFFAOYSA-N 0.000 claims description 5
- YMYVQVOEHLUWHB-UHFFFAOYSA-N 6-[(4-propan-2-ylphenyl)methyl]-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C(C)C)=CC=C1CC1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 YMYVQVOEHLUWHB-UHFFFAOYSA-N 0.000 claims description 5
- YLEOEWIGCWPIKB-UHFFFAOYSA-N 6-benzyl-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1CC1=CC=CC=C1 YLEOEWIGCWPIKB-UHFFFAOYSA-N 0.000 claims description 5
- OFGTXURSNNZGJA-UHFFFAOYSA-N 6-butyl-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCCC1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 OFGTXURSNNZGJA-UHFFFAOYSA-N 0.000 claims description 5
- YUNLLPZTVDNFPS-UHFFFAOYSA-N 6-pentyl-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCCCC1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 YUNLLPZTVDNFPS-UHFFFAOYSA-N 0.000 claims description 5
- CBCWBRJFCGBDQW-UHFFFAOYSA-N 7-(3,5-dichlorophenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC(Cl)=CC(Cl)=C1 CBCWBRJFCGBDQW-UHFFFAOYSA-N 0.000 claims description 5
- GHKGPSCOUDCKFA-UHFFFAOYSA-N 7-(3-methoxyphenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(C=2C(=CC3=C(N)N=CN=C3N=2)C=2C=CC(C)=CC=2)=C1 GHKGPSCOUDCKFA-UHFFFAOYSA-N 0.000 claims description 5
- SJOIOCWKCMUFTE-UHFFFAOYSA-N 7-(4-butoxyphenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 SJOIOCWKCMUFTE-UHFFFAOYSA-N 0.000 claims description 5
- LOUZSLNNZAHIGH-UHFFFAOYSA-N 7-(4-methoxyphenyl)-6-(3-phenylpropyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=NC2=NC=NC(N)=C2C=C1CCCC1=CC=CC=C1 LOUZSLNNZAHIGH-UHFFFAOYSA-N 0.000 claims description 5
- NXLDDXMRBCORMV-UHFFFAOYSA-N 7-(4-methoxyphenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 NXLDDXMRBCORMV-UHFFFAOYSA-N 0.000 claims description 5
- NOIMMUBOIPBZAU-UHFFFAOYSA-N 7-(4-methoxyphenyl)-6-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=CS1 NOIMMUBOIPBZAU-UHFFFAOYSA-N 0.000 claims description 5
- GKRJONNOKMRTIB-UHFFFAOYSA-N 7-(5-nitrothiophen-2-yl)-6-(4-propan-2-ylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C(C)C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C([N+]([O-])=O)S1 GKRJONNOKMRTIB-UHFFFAOYSA-N 0.000 claims description 5
- PLPVTHZVWWMXSP-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(2-methylpropyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound CC(C)CC1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 PLPVTHZVWWMXSP-UHFFFAOYSA-N 0.000 claims description 5
- KEQLQLBJQHZYQF-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(2-phenylethyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1CCC1=CC=CC=C1 KEQLQLBJQHZYQF-UHFFFAOYSA-N 0.000 claims description 5
- RLAKJZCVKPWPDD-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(3-fluorophenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=CC(F)=C1 RLAKJZCVKPWPDD-UHFFFAOYSA-N 0.000 claims description 5
- VMYDETZVFWKUOW-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(3-nitrophenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=CC([N+]([O-])=O)=C1 VMYDETZVFWKUOW-UHFFFAOYSA-N 0.000 claims description 5
- XICUWRCHWQOBNS-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(3-phenylpropyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1CCCC1=CC=CC=C1 XICUWRCHWQOBNS-UHFFFAOYSA-N 0.000 claims description 5
- UDDRCSTZBXJPHN-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(4-fluorophenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(F)C=C1 UDDRCSTZBXJPHN-UHFFFAOYSA-N 0.000 claims description 5
- JHSRINSHMPCCTR-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 JHSRINSHMPCCTR-UHFFFAOYSA-N 0.000 claims description 5
- VJWDZEXCLTXONM-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(4-propylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(CCC)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 VJWDZEXCLTXONM-UHFFFAOYSA-N 0.000 claims description 5
- GKBWGMHGJMOLAZ-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-phenylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=CC=C1 GKBWGMHGJMOLAZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 210000004351 coronary vessel Anatomy 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- UEHSRXSBZPPOGW-UHFFFAOYSA-N n-[4-[4-amino-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 UEHSRXSBZPPOGW-UHFFFAOYSA-N 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 229930192474 thiophene Natural products 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical group CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims description 4
- DPZYLEIWHTWHCU-UHFFFAOYSA-N 3-ethenylpyridine Chemical group C=CC1=CC=CN=C1 DPZYLEIWHTWHCU-UHFFFAOYSA-N 0.000 claims description 4
- HEGQLDZTGISPFX-UHFFFAOYSA-N 4-[4-amino-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-7-yl]benzonitrile Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(C#N)C=C1 HEGQLDZTGISPFX-UHFFFAOYSA-N 0.000 claims description 4
- XAUOXIPYRGOSCJ-UHFFFAOYSA-N 4-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-6-yl]butanenitrile Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1CCCC#N XAUOXIPYRGOSCJ-UHFFFAOYSA-N 0.000 claims description 4
- NGKCUSNUWWMKTD-UHFFFAOYSA-N 6,7-bis(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(C)C=C1 NGKCUSNUWWMKTD-UHFFFAOYSA-N 0.000 claims description 4
- ZMIXZCOYFOZFGM-UHFFFAOYSA-N 6,7-bis[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 ZMIXZCOYFOZFGM-UHFFFAOYSA-N 0.000 claims description 4
- RWOHTIHBTFBNRA-UHFFFAOYSA-N 6,7-dithiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C=1C=CSC=1C=1C=C2C(N)=NC=NC2=NC=1C1=CC=CS1 RWOHTIHBTFBNRA-UHFFFAOYSA-N 0.000 claims description 4
- CEBIAKBLUBTZQG-UHFFFAOYSA-N 6-(1,3-benzodioxol-5-yl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(OCO2)C2=C1 CEBIAKBLUBTZQG-UHFFFAOYSA-N 0.000 claims description 4
- JBLDXHHDTNCGHA-UHFFFAOYSA-N 6-(1,3-benzodioxol-5-yl)-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C=1C=C2OCOC2=CC=1C=1C=C2C(N)=NC=NC2=NC=1C1=CC=CS1 JBLDXHHDTNCGHA-UHFFFAOYSA-N 0.000 claims description 4
- RMFZDAICXLQMRC-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 RMFZDAICXLQMRC-UHFFFAOYSA-N 0.000 claims description 4
- MIOPCKKTKOHHHE-UHFFFAOYSA-N 6-(3-bromo-4-methoxyphenyl)-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=C(Br)C(OC)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 MIOPCKKTKOHHHE-UHFFFAOYSA-N 0.000 claims description 4
- XZQOWGMQVPMCBA-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(3-phenoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CC(OC=2C=CC=CC=2)=C1 XZQOWGMQVPMCBA-UHFFFAOYSA-N 0.000 claims description 4
- RTVCRTFJFBWXNS-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(4-methylsulfanylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(SC)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 RTVCRTFJFBWXNS-UHFFFAOYSA-N 0.000 claims description 4
- LWMBPRNRLBHNKE-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(4-nitrophenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C([N+]([O-])=O)C=C1 LWMBPRNRLBHNKE-UHFFFAOYSA-N 0.000 claims description 4
- HLACCPYDNZXOCN-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(4-phenoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 HLACCPYDNZXOCN-UHFFFAOYSA-N 0.000 claims description 4
- CUROOSTVSTZJQL-UHFFFAOYSA-N 6-(4-methylphenyl)-7-(5-methylthiophen-2-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound S1C(C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 CUROOSTVSTZJQL-UHFFFAOYSA-N 0.000 claims description 4
- JPOUMZBYXNXHKR-UHFFFAOYSA-N 6-(4-methylphenyl)-7-[4-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(C(F)(F)F)C=C1 JPOUMZBYXNXHKR-UHFFFAOYSA-N 0.000 claims description 4
- NEDZPTROAMDUNY-UHFFFAOYSA-N 6-(4-methylphenyl)-7-phenylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CC=C1 NEDZPTROAMDUNY-UHFFFAOYSA-N 0.000 claims description 4
- JRLCWHHCBBBIGL-UHFFFAOYSA-N 6-(4-methylphenyl)-7-pyridin-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CC=N1 JRLCWHHCBBBIGL-UHFFFAOYSA-N 0.000 claims description 4
- BNDYPQBHKQFBNA-UHFFFAOYSA-N 6-(4-methylphenyl)-7-pyridin-3-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CN=C1 BNDYPQBHKQFBNA-UHFFFAOYSA-N 0.000 claims description 4
- WKNDFOXQMZFDQX-UHFFFAOYSA-N 6-(4-methylphenyl)-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 WKNDFOXQMZFDQX-UHFFFAOYSA-N 0.000 claims description 4
- OZPATYYNBNCREL-UHFFFAOYSA-N 6-(4-methylphenyl)-7-thiophen-3-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CSC=C1 OZPATYYNBNCREL-UHFFFAOYSA-N 0.000 claims description 4
- YUAALMIPTRVMDD-UHFFFAOYSA-N 6-(4-propan-2-ylphenyl)-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C(C)C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 YUAALMIPTRVMDD-UHFFFAOYSA-N 0.000 claims description 4
- LZNSOVAHFMAUKZ-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C(C)(C)C)C=C1 LZNSOVAHFMAUKZ-UHFFFAOYSA-N 0.000 claims description 4
- XBHRETXSEPDLFI-UHFFFAOYSA-N 6-[(3-methoxyphenyl)methyl]-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(CC=2C(=NC3=NC=NC(N)=C3C=2)C=2SC=CC=2)=C1 XBHRETXSEPDLFI-UHFFFAOYSA-N 0.000 claims description 4
- SPZWAXXUCPNACP-UHFFFAOYSA-N 6-[(4-bromophenyl)methyl]-7-(1,3-thiazol-2-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C=1C=C(Br)C=CC=1CC=1C=C2C(N)=NC=NC2=NC=1C1=NC=CS1 SPZWAXXUCPNACP-UHFFFAOYSA-N 0.000 claims description 4
- PBNAJSJULPECOR-UHFFFAOYSA-N 6-[(4-methoxyphenyl)methyl]-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1CC1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 PBNAJSJULPECOR-UHFFFAOYSA-N 0.000 claims description 4
- JEURLXBZQRWMBJ-UHFFFAOYSA-N 6-[4-(dimethylamino)phenyl]-7-pyridin-4-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=NC=C1 JEURLXBZQRWMBJ-UHFFFAOYSA-N 0.000 claims description 4
- WTGDFCWBOKKADF-UHFFFAOYSA-N 6-[4-(dimethylamino)phenyl]-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 WTGDFCWBOKKADF-UHFFFAOYSA-N 0.000 claims description 4
- CDCQKGPSUUGPFT-UHFFFAOYSA-N 6-butyl-7-thiophen-3-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCCC1=CC2=C(N)N=CN=C2N=C1C=1C=CSC=1 CDCQKGPSUUGPFT-UHFFFAOYSA-N 0.000 claims description 4
- GSJMEJPHDCYTSV-UHFFFAOYSA-N 6-tert-butyl-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CC(C)(C)C1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 GSJMEJPHDCYTSV-UHFFFAOYSA-N 0.000 claims description 4
- CETZFJSIIQXIEZ-UHFFFAOYSA-N 7-(1,3-benzodioxol-5-yl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(OCO2)C2=C1 CETZFJSIIQXIEZ-UHFFFAOYSA-N 0.000 claims description 4
- BTSWCBHWUYKIKO-UHFFFAOYSA-N 7-(1-benzofuran-2-yl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC2=CC=CC=C2O1 BTSWCBHWUYKIKO-UHFFFAOYSA-N 0.000 claims description 4
- KQWPSOCLXDLSKT-UHFFFAOYSA-N 7-(3-chlorophenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CC(Cl)=C1 KQWPSOCLXDLSKT-UHFFFAOYSA-N 0.000 claims description 4
- UIIHAAQVECYSLX-UHFFFAOYSA-N 7-(4-aminophenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N)C=C1 UIIHAAQVECYSLX-UHFFFAOYSA-N 0.000 claims description 4
- UUMKMONTEOXNHT-UHFFFAOYSA-N 7-(4-bromophenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(Br)C=C1 UUMKMONTEOXNHT-UHFFFAOYSA-N 0.000 claims description 4
- RPHKDMPUSNNCLH-UHFFFAOYSA-N 7-(4-bromophenyl)-6-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(Br)C=C1 RPHKDMPUSNNCLH-UHFFFAOYSA-N 0.000 claims description 4
- HWWKRKBFSAYUNE-UHFFFAOYSA-N 7-(4-bromothiophen-2-yl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC(Br)=CS1 HWWKRKBFSAYUNE-UHFFFAOYSA-N 0.000 claims description 4
- SVZHLGSZOFNTLA-UHFFFAOYSA-N 7-(4-chlorophenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(Cl)C=C1 SVZHLGSZOFNTLA-UHFFFAOYSA-N 0.000 claims description 4
- POTAUMNCNLCMRB-UHFFFAOYSA-N 7-(4-ethylphenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(CC)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 POTAUMNCNLCMRB-UHFFFAOYSA-N 0.000 claims description 4
- XRFBTSMBQVQABN-UHFFFAOYSA-N 7-(4-fluorophenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(F)C=C1 XRFBTSMBQVQABN-UHFFFAOYSA-N 0.000 claims description 4
- OOISDCHPHZYNSU-UHFFFAOYSA-N 7-(5-bromothiophen-2-yl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(Br)S1 OOISDCHPHZYNSU-UHFFFAOYSA-N 0.000 claims description 4
- ARDJIPWJAVDBGB-UHFFFAOYSA-N 7-(5-methylfuran-2-yl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound O1C(C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=C(C)C=C1 ARDJIPWJAVDBGB-UHFFFAOYSA-N 0.000 claims description 4
- HKGPVDYRCFXKCR-UHFFFAOYSA-N 7-(furan-2-yl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=CO1 HKGPVDYRCFXKCR-UHFFFAOYSA-N 0.000 claims description 4
- VLORDBYXPWWTPX-UHFFFAOYSA-N 7-(furan-3-yl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=COC=C1 VLORDBYXPWWTPX-UHFFFAOYSA-N 0.000 claims description 4
- OWINKNRJAIVLGD-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(3-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(C=2C(=NC3=NC=NC(N)=C3C=2)C=2C=CC(=CC=2)N(C)C)=C1 OWINKNRJAIVLGD-UHFFFAOYSA-N 0.000 claims description 4
- CKEGITSFPLSKNR-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(3-phenylmethoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC=CC(OCC=2C=CC=CC=2)=C1 CKEGITSFPLSKNR-UHFFFAOYSA-N 0.000 claims description 4
- ZADGRKLNRFXWQT-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-(4-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 ZADGRKLNRFXWQT-UHFFFAOYSA-N 0.000 claims description 4
- DQDVBKKBGUQXEQ-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-[(3-methoxyphenyl)methyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(CC=2C(=NC3=NC=NC(N)=C3C=2)C=2C=CC(=CC=2)N(C)C)=C1 DQDVBKKBGUQXEQ-UHFFFAOYSA-N 0.000 claims description 4
- XDJGZINTMXJBED-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-hexylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCCCCC1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 XDJGZINTMXJBED-UHFFFAOYSA-N 0.000 claims description 4
- ILHQNMFCHYGZCS-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-pentylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCCCC1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 ILHQNMFCHYGZCS-UHFFFAOYSA-N 0.000 claims description 4
- OGYXFQRUSISPCZ-UHFFFAOYSA-N 7-[4-(dimethylamino)phenyl]-6-propylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCC1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 OGYXFQRUSISPCZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 206010014523 Embolism and thrombosis Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 150000003855 acyl compounds Chemical class 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 4
- 230000002152 alkylating effect Effects 0.000 claims description 4
- 150000008064 anhydrides Chemical group 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 208000009935 visceral pain Diseases 0.000 claims description 4
- WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 claims description 3
- FJPCBSHLYKYWOI-UHFFFAOYSA-N 6-hexyl-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCCCCC1=CC2=C(N)N=CN=C2N=C1C1=CC=CS1 FJPCBSHLYKYWOI-UHFFFAOYSA-N 0.000 claims description 3
- LDAXOGINXHQTAH-UHFFFAOYSA-N 7-(3,5-dimethoxyphenyl)-6-(4-methylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(C=2C(=CC3=C(N)N=CN=C3N=2)C=2C=CC(C)=CC=2)=C1 LDAXOGINXHQTAH-UHFFFAOYSA-N 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 238000007887 coronary angioplasty Methods 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 125000005544 phthalimido group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000008629 immune suppression Effects 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 230000037324 pain perception Effects 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- JSRLURSZEMLAFO-UHFFFAOYSA-N 1,3-dibromobenzene Chemical compound BrC1=CC=CC(Br)=C1 JSRLURSZEMLAFO-UHFFFAOYSA-N 0.000 claims 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical compound C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 claims 2
- LTNQPJXKRGOPDX-UHFFFAOYSA-N 6-benzyl-7-thiophen-2-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C=1C=CC=CC=1CC=1C=C2C(N)=NC=NC2=NC=1C1=CC=CS1 LTNQPJXKRGOPDX-UHFFFAOYSA-N 0.000 claims 2
- HJKGBRPNSJADMB-UHFFFAOYSA-N beta-Phenylpyridine Natural products C1=CC=CC=C1C1=CC=CN=C1 HJKGBRPNSJADMB-UHFFFAOYSA-N 0.000 claims 2
- OIMWEHOYHJJPJD-UHFFFAOYSA-N pyridine;pyrimidine Chemical compound C1=CC=NC=C1.C1=CN=CN=C1 OIMWEHOYHJJPJD-UHFFFAOYSA-N 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- YTZKOQUCBOVLHL-UHFFFAOYSA-N tert-butylbenzene Chemical group CC(C)(C)C1=CC=CC=C1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 108010076278 Adenosine kinase Proteins 0.000 abstract description 48
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 abstract description 47
- 102100032534 Adenosine kinase Human genes 0.000 abstract description 47
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 208000002193 Pain Diseases 0.000 abstract description 16
- 230000036407 pain Effects 0.000 abstract description 16
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 68
- 230000000694 effects Effects 0.000 description 37
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 36
- 229960005305 adenosine Drugs 0.000 description 36
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 32
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 25
- 239000002253 acid Substances 0.000 description 24
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 239000003121 adenosine kinase inhibitor Substances 0.000 description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 125000003282 alkyl amino group Chemical group 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 239000004327 boric acid Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- DGHLQCSKEMTMIS-UHFFFAOYSA-N 5-iodopyrimidine-4,6-diamine Chemical compound NC1=NC=NC(N)=C1I DGHLQCSKEMTMIS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000004962 physiological condition Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- WFDWKVHMQUPSBZ-UHFFFAOYSA-N C=C.B(O)O Chemical class C=C.B(O)O WFDWKVHMQUPSBZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003502 anti-nociceptive effect Effects 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 150000004694 iodide salts Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000003040 nociceptive effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000004963 pathophysiological condition Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- 108010060263 Adenosine A1 Receptor Proteins 0.000 description 3
- 102000030814 Adenosine A1 receptor Human genes 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000008050 dialkyl sulfates Chemical class 0.000 description 3
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 229960003883 furosemide Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical group C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 2
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 2
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 2
- ZOVHGFCXPXOKKU-UHFFFAOYSA-N 2-bromothiophene;thiophene Chemical compound C=1C=CSC=1.BrC1=CC=CS1 ZOVHGFCXPXOKKU-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 2
- PJRGDKFLFAYRBV-UHFFFAOYSA-N 2-phenylthiophene Chemical compound C1=CSC(C=2C=CC=CC=2)=C1 PJRGDKFLFAYRBV-UHFFFAOYSA-N 0.000 description 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical group C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- NLQLNIRVMDWHJE-UHFFFAOYSA-N 2-sulfanylidene-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound C1=CC=C2C(=O)NC(=S)NC2=N1 NLQLNIRVMDWHJE-UHFFFAOYSA-N 0.000 description 2
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- VHKSWAHRKCPYNJ-UHFFFAOYSA-N 5,7-bis(4-fluorophenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C=12C(N)=NC=NC2=NC(C=2C=CC(F)=CC=2)=CC=1C1=CC=C(F)C=C1 VHKSWAHRKCPYNJ-UHFFFAOYSA-N 0.000 description 2
- VKCKOQWDPGZVNS-UHFFFAOYSA-N 5,7-diphenylpyrido[2,3-d]pyrimidin-4-amine Chemical class C=12C(N)=NC=NC2=NC(C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 VKCKOQWDPGZVNS-UHFFFAOYSA-N 0.000 description 2
- QQNHHTITJWPFCU-UHFFFAOYSA-N 5-(2-phenylethenyl)pyrimidine-4,6-diamine Chemical compound NC1=NC=NC(N)=C1C=CC1=CC=CC=C1 QQNHHTITJWPFCU-UHFFFAOYSA-N 0.000 description 2
- YAGLXWHLIRRHHQ-UHFFFAOYSA-N 5-(4-chlorophenyl)-7-(4-nitrophenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C=12C(N)=NC=NC2=NC(C=2C=CC(=CC=2)[N+]([O-])=O)=CC=1C1=CC=C(Cl)C=C1 YAGLXWHLIRRHHQ-UHFFFAOYSA-N 0.000 description 2
- KIPMVOXROSGIKU-UHFFFAOYSA-N 5-(4-methoxyphenyl)-7-(4-nitrophenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C1=CC(C=2C=CC(=CC=2)[N+]([O-])=O)=NC2=NC=NC(N)=C12 KIPMVOXROSGIKU-UHFFFAOYSA-N 0.000 description 2
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 2
- FXJTXZUMECXSTN-UHFFFAOYSA-N 6-(3,5-dichlorophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=NC=NC(N)=C2C=C1C1=CC(Cl)=CC(Cl)=C1 FXJTXZUMECXSTN-UHFFFAOYSA-N 0.000 description 2
- BLCNKWLEIKKKEW-UHFFFAOYSA-N 6-butyl-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound CCCCC1=CC2=C(N)N=CN=C2N=C1C1=CC=C(N(C)C)C=C1 BLCNKWLEIKKKEW-UHFFFAOYSA-N 0.000 description 2
- GWMCUGARSTVDPA-UHFFFAOYSA-N 7-(4-bromophenyl)-5-(4-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical class C1=CC(OC)=CC=C1C1=CC(C=2C=CC(Br)=CC=2)=NC2=NC=NC(N)=C12 GWMCUGARSTVDPA-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical group C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 2
- VKIJXFIYBAYHOE-VOTSOKGWSA-N [(e)-2-phenylethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=CC=C1 VKIJXFIYBAYHOE-VOTSOKGWSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000000033 alkoxyamino group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003432 anti-folate effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940127074 antifolate Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 150000002240 furans Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 230000006609 metabolic stress Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- MCLITRXWHZUNCQ-UHFFFAOYSA-N methylcyanamide Chemical compound CNC#N MCLITRXWHZUNCQ-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- LWUUXENGQFMODR-UHFFFAOYSA-N n-(2-cyanoethyl)formamide Chemical group O=CNCCC#N LWUUXENGQFMODR-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 230000037125 natural defense Effects 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000012753 partial hepatectomy Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000002212 purine nucleoside Substances 0.000 description 2
- JQSBVBURTZTVJQ-UHFFFAOYSA-N pyridine;pyrrolidine Chemical group C1CCNC1.C1=CC=NC=C1 JQSBVBURTZTVJQ-UHFFFAOYSA-N 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000021317 sensory perception Effects 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940001593 sodium carbonate Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001768 subcellular fraction Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000019432 tissue death Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZROGCHDPRZRKTI-UHFFFAOYSA-N 1,4-dibutoxybenzene Chemical compound CCCCOC1=CC=C(OCCCC)C=C1 ZROGCHDPRZRKTI-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NRMGFQFLHNYNCY-UHFFFAOYSA-N 2-hydroxyethanesulfonic acid;hydroiodide Chemical compound I.OCCS(O)(=O)=O NRMGFQFLHNYNCY-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ATFSPXYPCWTOBR-UHFFFAOYSA-N 2-thiophen-2-ylpyrido[2,3-d]pyrimidine Chemical compound C1=CSC(C=2N=C3N=CC=CC3=CN=2)=C1 ATFSPXYPCWTOBR-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- CHTSWZNXEKOLPM-UHFFFAOYSA-N 5-nitrothiophene-2-carbaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)S1 CHTSWZNXEKOLPM-UHFFFAOYSA-N 0.000 description 1
- ICVYKJSDWGGRNE-UHFFFAOYSA-N 6-chloro-5-iodopyrimidin-4-amine Chemical compound NC1=NC=NC(Cl)=C1I ICVYKJSDWGGRNE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001264 acyl cyanides Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- VCSZKSHWUBFOOE-UHFFFAOYSA-N dioxidanium;sulfate Chemical compound O.O.OS(O)(=O)=O VCSZKSHWUBFOOE-UHFFFAOYSA-N 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- YFXCNIVBAVFOBX-UHFFFAOYSA-N ethenylboronic acid Chemical class OB(O)C=C YFXCNIVBAVFOBX-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical class COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- BOTNYLSAWDQNEX-UHFFFAOYSA-N phenoxymethylbenzene Chemical compound C=1C=CC=CC=1COC1=CC=CC=C1 BOTNYLSAWDQNEX-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83439397A | 1997-04-16 | 1997-04-16 | |
US08/834,393 | 1997-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1259948A true CN1259948A (zh) | 2000-07-12 |
Family
ID=25266829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98806072A Pending CN1259948A (zh) | 1997-04-16 | 1998-04-16 | 6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0979230A1 (xx) |
JP (1) | JP2001520649A (xx) |
KR (1) | KR20010006453A (xx) |
CN (1) | CN1259948A (xx) |
AR (1) | AR012435A1 (xx) |
AU (1) | AU744528B2 (xx) |
BG (1) | BG103861A (xx) |
BR (1) | BR9809088A (xx) |
CA (1) | CA2287465A1 (xx) |
CO (1) | CO4940439A1 (xx) |
HU (1) | HUP0001402A3 (xx) |
IL (1) | IL131892A0 (xx) |
NO (1) | NO995033L (xx) |
NZ (1) | NZ337844A (xx) |
PL (1) | PL336262A1 (xx) |
SK (1) | SK142099A3 (xx) |
TR (1) | TR199902456T2 (xx) |
TW (1) | TW458977B (xx) |
WO (1) | WO1998046603A1 (xx) |
ZA (1) | ZA982912B (xx) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100376571C (zh) * | 2001-02-12 | 2008-03-26 | 霍夫曼-拉罗奇有限公司 | 6-取代的吡啶并嘧啶类化合物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057040A1 (en) * | 2000-02-03 | 2001-08-09 | Abbott Laboratories | 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
KR20070086076A (ko) | 2004-11-12 | 2007-08-27 | 트러스티즈 오브 터프츠 칼리지 | 리파아제 억제제 |
EP2139332A4 (en) * | 2007-03-28 | 2010-04-21 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |
BR112015007182A2 (pt) * | 2012-10-05 | 2017-07-04 | Rigel Pharmaceuticals Inc | inibidores de gdf-8 |
WO2017205848A1 (en) * | 2016-05-27 | 2017-11-30 | Legacy Emanuel Hospital & Health Center | Methanocarba derivatives of pseudoribose that inhibit adenosine kinase |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB774094A (en) * | 1953-01-02 | 1957-05-08 | Wellcome Found | Improvements in or relating to pyrimidine compounds |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
-
1998
- 1998-03-27 TW TW087104674A patent/TW458977B/zh not_active IP Right Cessation
- 1998-04-06 ZA ZA982912A patent/ZA982912B/xx unknown
- 1998-04-14 CO CO98020309A patent/CO4940439A1/es unknown
- 1998-04-15 AR ARP980101732A patent/AR012435A1/es unknown
- 1998-04-16 BR BR9809088-7A patent/BR9809088A/pt not_active IP Right Cessation
- 1998-04-16 NZ NZ337844A patent/NZ337844A/en unknown
- 1998-04-16 TR TR1999/02456T patent/TR199902456T2/xx unknown
- 1998-04-16 AU AU70981/98A patent/AU744528B2/en not_active Ceased
- 1998-04-16 KR KR1019997009543A patent/KR20010006453A/ko not_active Application Discontinuation
- 1998-04-16 WO PCT/US1998/004127 patent/WO1998046603A1/en not_active Application Discontinuation
- 1998-04-16 IL IL13189298A patent/IL131892A0/xx unknown
- 1998-04-16 JP JP54387898A patent/JP2001520649A/ja active Pending
- 1998-04-16 PL PL98336262A patent/PL336262A1/xx unknown
- 1998-04-16 CA CA002287465A patent/CA2287465A1/en not_active Abandoned
- 1998-04-16 HU HU0001402A patent/HUP0001402A3/hu unknown
- 1998-04-16 EP EP98917950A patent/EP0979230A1/en not_active Withdrawn
- 1998-04-16 CN CN98806072A patent/CN1259948A/zh active Pending
- 1998-04-16 SK SK1420-99A patent/SK142099A3/sk unknown
-
1999
- 1999-10-15 NO NO995033A patent/NO995033L/no not_active Application Discontinuation
- 1999-11-05 BG BG103861A patent/BG103861A/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100376571C (zh) * | 2001-02-12 | 2008-03-26 | 霍夫曼-拉罗奇有限公司 | 6-取代的吡啶并嘧啶类化合物 |
Also Published As
Publication number | Publication date |
---|---|
TW458977B (en) | 2001-10-11 |
KR20010006453A (ko) | 2001-01-26 |
AU744528B2 (en) | 2002-02-28 |
PL336262A1 (en) | 2000-06-19 |
ZA982912B (en) | 1998-10-09 |
BG103861A (en) | 2000-06-30 |
AR012435A1 (es) | 2000-10-18 |
EP0979230A1 (en) | 2000-02-16 |
TR199902456T2 (xx) | 2000-07-21 |
BR9809088A (pt) | 2000-08-01 |
NO995033D0 (no) | 1999-10-15 |
SK142099A3 (en) | 2000-05-16 |
NZ337844A (en) | 2001-11-30 |
CO4940439A1 (es) | 2000-07-24 |
JP2001520649A (ja) | 2001-10-30 |
NO995033L (no) | 1999-12-15 |
HUP0001402A2 (hu) | 2000-10-28 |
IL131892A0 (en) | 2001-03-19 |
CA2287465A1 (en) | 1998-10-22 |
HUP0001402A3 (en) | 2001-01-29 |
AU7098198A (en) | 1998-11-11 |
WO1998046603A1 (en) | 1998-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100351250C (zh) | 对gsk3具有选择性抑制作用的新型化合物 | |
EP1355889B1 (en) | Substituted triazole diamine derivatives as kinase inhibitors | |
TWI519515B (zh) | B型肝炎抗病毒劑 | |
EP2296653B1 (en) | Compounds and methods for treating inflammatory and fibrotic disorders | |
CA2939219C (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
KR100667645B1 (ko) | 환상 아민 ccr3 길항제 | |
EP2620433B1 (en) | Substituted amide compound | |
JP2008510018A (ja) | フルクトース−1,6−ビスホスファターゼの新規チアゾール阻害物質 | |
CN1283192A (zh) | 用芳基取代或杂芳基取代的杂环脲抑制raf激酶 | |
JP2000501694A (ja) | 複素環置換シクロペンタン化合物 | |
AU2024202745A1 (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
JP2001520655A (ja) | 5,7−ジ置換4−アミノピリド[2,3−d]ピリミジン化合物およびアデノシンキナーゼ阻害剤としてのその用途 | |
WO2006071035A1 (en) | Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives | |
JP2014507453A (ja) | 1H−ピロロ[3,2−d]ピリミジンジオン誘導体 | |
JPWO2014133134A1 (ja) | 新規テトラヒドロピリドピリミジノン誘導体 | |
CN1259948A (zh) | 6,7-二取代-4-氨基吡啶并[2,3-d]嘧啶化合物 | |
KR20210126636A (ko) | 이환식 설폰아마이드 | |
EP1908752A1 (en) | Novel 2-quinolone derivative | |
JP2003212846A (ja) | 縮合環化合物及びc型肝炎治療剤 | |
US6030969A (en) | 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds | |
JP4518587B2 (ja) | 2−フェニルモルホリン誘導体 | |
JP2001520654A (ja) | 5,6,7−三置換−4−アミノピリド[2,3−d]ピリミジン化合物 | |
CZ360199A3 (cs) | Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu | |
CZ350899A3 (cs) | 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny | |
MXPA99009512A (en) | 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |